Study guide
6.1 Hypoxic-Ischemic Encephalopathy (HIE) & Therapeutic Hypothermia
NCC Low Risk Neonatal Nursing RNC-LRN
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Maternal-Fetal Risk Assessment
1.1 RNC-LRN Exam Structure, Eligibility & Test Blueprint 1.2 Maternal Health Conditions & Prenatal Risk Factors 1.3 Intrapartum Events & Fetal Surveillance Interpretation 1.4 Antepartum Fetal Surveillance, Labor Progression & Perinatal Screening
2 Chapter 2: Comprehensive Neonatal Assessment & Gestational Age
2.1 Physical Assessment & Normal Variations vs. Abnormalities 2.2 Gestational Age Assessment: New Ballard Score & Maturity Classification 2.3 Neurobehavioral Assessment & Primitive Reflexes
3 Chapter 3: Neonatal Diagnostic & Laboratory Evaluation
3.1 Neonatal Blood Gas Interpretation & Acid-Base Balance 3.2 Hematologic & Metabolic Laboratory Diagnostics 3.3 Newborn Screening & Diagnostic Imaging Modalities
4 Chapter 4: Neonatal Respiratory Pathophysiology & Management
4.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency 4.2 Transient Tachypnea of the Newborn (TTN) 4.3 Meconium Aspiration Syndrome (MAS) & Air Leaks 4.4 Apnea of Prematurity (AOP) & Persistent Pulmonary Hypertension (PPHN) 4.5 Oxygenation Assessment & Non-Invasive Respiratory Support
5 Chapter 5: Neonatal Cardiovascular Conditions & Hemodynamics
5.1 Fetal-to-Neonatal Circulatory Transition & Innocent Murmurs 5.2 Patent Ductus Arteriosus (PDA) & Ductal-Dependent Cardiac Lesions 5.3 Congenital Heart Defects & CCHD Pulse Oximetry Screening
6 Chapter 6: Neurologic & Gastrointestinal/Genitourinary Disorders
6.1 Hypoxic-Ischemic Encephalopathy (HIE) & Therapeutic Hypothermia 6.2 Neonatal Seizures & Intraventricular Hemorrhage (IVH) 6.3 Gastrointestinal Pathologies & Necrotizing Enterocolitis (NEC) 6.4 Congenital GI/GU Anomalies & Renal Function
7 Chapter 7: Hematology, Hyperbilirubinemia, and Genetic/Endocrine Conditions
7.1 Neonatal Hyperbilirubinemia & Kernicterus Risk 7.2 Hemolytic Disease & Neonatal Hematologic Disorders 7.3 Inborn Errors of Metabolism & Endocrine Disorders 7.4 Infant of a Diabetic Mother (IDM) & Chromosomal Anomalies
8 Chapter 8: Resuscitation & Immediate Neonatal Stabilization
8.1 Neonatal Resuscitation Program (NRP) 9th Edition Core Algorithm 8.2 Advanced Resuscitation: Chest Compressions & Emergency Medications 8.3 Post-Resuscitation Stabilization & The S.T.A.B.L.E. Framework
9 Chapter 9: Nutrition, Feeding & Gastrointestinal Support
9.1 Maternal Breast Milk, Lactation Support & Donor Milk 9.2 Nutritional Fortification & Specialized Formula Selection 9.3 Enteral Feeding Methods, Trophic Feeds & Gavage Administration
10 Chapter 10: Thermoregulation, Fluids, Electrolytes & Glucose Management
10.1 Thermoregulation & Prevention of Cold Stress 10.2 Fluid Requirements & Electrolyte Management 10.3 Neonatal Hypoglycemia Assessment & Management Protocols
11 Chapter 11: Infection Control, Sepsis & Neonatal Pharmacology
11.1 Early-Onset vs. Late-Onset Sepsis & Maternal GBS Management 11.2 Infection Prevention, CLABSI Bundles & Antimicrobial Stewardship 11.3 Neonatal Pharmacology & High-Alert Medication Administration 11.4 Congenital & Perinatal Infections, Sexually Transmitted Infections and Immune Function 11.5 Vitamin K, Eye Prophylaxis, Immunization & Routine Neonatal Medications
12 Chapter 12: Neurodevelopmental Care, Family-Centered Care & Discharge Transition
12.1 Developmental Care, Stress Reduction & Non-Pharmacologic Pain Management 12.2 Neonatal Abstinence Syndrome (NAS/NOWS) & Eat, Sleep, Console (ESC) 12.3 Discharge Readiness, Car Seat Challenge & Safe Sleep Education 12.4 Psychosocial Support, Family Adaptation & Perinatal Grief 12.5 Home Care Technology, Developmental Follow-Up & Community Referral
13 Chapter 13: Professional Issues, Safety, Quality & Ethics in Neonatal Nursing
13.1 Patient Safety, Error Prevention & Quality Improvement 13.2 Bioethics, Legal Standards & Family Advocacy
14 Chapter 14: Musculoskeletal, Integumentary & Birth Injury Conditions
14.1 Musculoskeletal Anomalies & Neonatal Birth Injuries 14.2 Neonatal Skin: Barrier Physiology, Normal Variations & Common Lesions
6.1 Hypoxic-Ischemic Encephalopathy (HIE) & Therapeutic Hypothermia
Key Takeaways Explain This Topic AI
Hypoxic-Ischemic Encephalopathy (HIE) develops in a distinct biphasic cascade: primary energy failure (acute ATP depletion, cytotoxic edema, glutamate excitotoxicity) is separated by a 1- to 6-hour latent therapeutic window before secondary energy failure (24–48 hours) triggers mitochondrial collapse, apoptosis, and secondary seizures.
Sarnat clinical staging categorizes HIE severity into Mild (Stage 1: hyperalert, jittery, tachycardia, normal EEG, >95% normal outcome), Moderate (Stage 2: lethargic, hypotonic, bradycardia, miosis, seizures in >50%, abnormal aEEG, 20–30% disability), and Severe (Stage 3: comatose, flaccid, absent brainstem reflexes, burst suppression aEEG, 50–75% mortality).
Therapeutic hypothermia (target core body temperature 33.5°C [range 33.0°C–34.0°C] for 72 hours initiated within 6 hours of birth) is the standard-of-care neuroprotective intervention for infants ≥35–36 weeks with moderate-to-severe encephalopathy and evidence of intrapartum asphyxia.
Targeted cooling induces expected systemic physiological changes including sinus bradycardia (HR 80–100 bpm), mild hypotension, hypokalemia during cooling, thrombocytopenia, and reduced hepatic/renal drug clearance.
Controlled rewarming must proceed slowly at a rate of 0.5°C every 1 to 2 hours over 6 to 8 hours to prevent rapid peripheral vasodilation, rebound hyperkalemia, acute hypotension, and the emergence of secondary seizures.
Last updated: August 2026
6.1 Hypoxic-Ischemic Encephalopathy (HIE) & Therapeutic Hypothermia
Hypoxic-Ischemic Encephalopathy (HIE) is a clinically defined syndrome of acute central nervous system dysfunction resulting from perinatal asphyxia. Perinatal asphyxia occurs when impaired placental gas exchange or acute intrapartum interruption of cerebral blood flow deprives the fetal brain of oxygen (hypoxemia) and substrate delivery (ischemia), resulting in progressive tissue acidosis. HIE remains one of the leading causes of neonatal mortality and permanent long-term neurodevelopmental disability, including cerebral palsy, epilepsy, cognitive delay, and visual or sensorineural hearing impairment.
1. Pathophysiology of Perinatal Asphyxia & the Triphasic Injury Cascade
Hypoxic-ischemic neuronal injury is not an instantaneous, single-point event; rather, it evolves through a defined chronological cascade consisting of primary energy failure, a latent therapeutic window, secondary energy failure, and a prolonged tertiary phase. +----------------------------------------------------------------------------------------------------+
- | THE TRIPHASIC HIE INJURY CASCADE |
- | |
- | [Primary Energy Failure] --> [Latent Phase Window] --> [Secondary Energy Failure] |
- | * Immediate asphyxial event * 1 to 6 Hours Post-Birth * 24 to 48 Hours Post-Birth |
- | * Severe ATP depletion * Transient ATP recovery * Mitochondrial failure |
- | * Na+/K+ ATPase pump failure * Normalizing metabolism * Apoptosis & Cytokine storm |
- | * Cytotoxic edema & Ca2+ influx * **THERAPEUTIC WINDOW** * Clinical/EEG Seizures |
- | * Glutamate excitotoxicity * **INITIATE COOLING** * Secondary brain swelling |
- +----------------------------------------------------------------------------------------------------+
- Phase 1: Primary Energy Failure (0 to 1 Hour)
Cellular Hypoxia & Anaerobic Glycolysis: When cerebral perfusion and arterial oxygen content plummet, oxidative phosphorylation within neuronal mitochondria ceases. The cell shifts to anaerobic glycolysis, which rapidly depletes intracellular glycogen stores and generates excessive lactic acid, causing profound intracellular metabolic acidosis.
Membrane Depolarization: Loss of high-energy adenosine triphosphate (ATP) leads to immediate failure of ATP-dependent active transport pumps, specifically the N a + / K + Na^+/K^+ N a + / K + ATPase pump and the C a 2 + / M g 2 + Ca^{2+}/Mg^{2+} C a 2 + / M g 2 + pump .
Cytotoxic Edema: Sodium and chloride ions enter the intracellular compartment along an uninhibited electrochemical gradient, drawing water passively into neurons and astrocytes, producing rapid cytotoxic cerebral edema .
Glutamate Excitotoxicity & Calcium Cascade: Massive presynaptic membrane depolarization triggers excessive release of the excitatory neurotransmitter glutamate into the synaptic cleft, while energy-depleted glial reuptake mechanisms fail. Glutamate overactivates postsynaptic N N N -methyl- D D D -aspartate ( NMDA ) and α \alpha α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ( AMPA ) receptors, opening ligand-gated calcium channels.
Intracellular Calcium Influx: The massive influx of intracellular free calcium ( C a 2 + Ca^{2+} C a 2 + ) activates destructive calcium-dependent enzymes, including phospholipases, calpains, endonucleases, and neuronal nitric oxide synthase (nNOS). These enzymes disrupt the cytoskeleton, degrade structural proteins, generate toxic free radicals (reactive oxygen and nitrogen species), and cause immediate acute necrotic cell death.
Phase 2: Latent Phase (The Therapeutic Window: 1 to 6 Hours)
Following successful neonatal resuscitation and stabilization, cerebral blood flow, oxygenation, and cellular ATP concentrations undergo a temporary, partial recovery.
The Critical Window of Opportunity: Despite apparent cellular stabilization, upstream biochemical cascades—such as microglial activation, mitochondrial membrane permeability transition, and caspase activation—have been set in motion. This 1- to 6-hour interval represents the narrow "therapeutic window" during which neuroprotective interventions (such as therapeutic hypothermia) can arrest downstream apoptotic cascades before secondary cellular destruction occurs.
Phase 3: Secondary Energy Failure (24 to 48 Hours)
Beginning approximately 6 to 24 hours after the initial insult and peaking at 24 to 48 hours, the brain undergoes secondary energy failure without any secondary hypoxic or hemodynamic trigger.
Mitochondrial Collapse & Apoptosis: Mitochondrial inner membrane pores open irreversibly (mitochondrial permeability transition pore opening), halting ATP synthesis, releasing cytochrome c into the cytosol, and assembling the apoptosome. This initiates the intrinsic apoptotic cascade via caspase-3 and caspase-9 activation.
Inflammatory Cytokine Storm: Activated microglia and infiltrating astrocytes release neurotoxic pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 beta (IL-1β), and Interleukin-6 (IL-6).
Clinical Manifestations: Secondary energy failure is characterized by the emergence of severe clinical and electrographic seizures , worsening cerebral edema with elevated intracranial pressure, loss of cerebral autoregulation, and progressive neurological deterioration.
Phase 4: Tertiary Phase (Weeks to Months)
Late remodeling characterized by persistent low-grade neuroinflammation, microglial sensitization, altered epigenetic programming, and impaired neurogenesis and oligodendroglial myelination, leading to long-term cerebral white matter injury (periventricular leukomalacia) and cortical atrophy.
2. Clinical Assessment & Sarnat Staging of Neonatal Encephalopathy
The severity of encephalopathy must be graded promptly after birth to guide therapeutic hypothermia eligibility and establish prognosis. The Sarnat and Sarnat Classification (1976) , modified in contemporary practice, classifies HIE into three distinct stages based on level of consciousness, muscle tone, primitive reflexes, autonomic function, and electroencephalographic (EEG) activity.
Modified Sarnat Staging System
Clinical Parameter Stage 1: Mild HIE Stage 2: Moderate HIE Stage 3: Severe HIE
Level of Consciousness Hyperalert, irritable, jittery, exaggerated response to stimuli Lethargic, obtunded, stuporous, diminished response to pain Comatose, completely unarousable, stupor, absent pain response
Neuromuscular Tone Normal or mildly increased (hypertonic) Hypotonic (moderate generalized flaccidity), weak head lag Flaccid (severe hypotonia), "rag-doll" posture, absent tone
Spontaneous Posture Mild distal flexion Flexion with weak spontaneous movements Decerebrate posturing (extension) or completely limp
- Primitive Reflexes
- Suck / Swallow Normal or hyperactive Weak, uncoordinated, or absent Completely absent
- Moro Reflex Exaggerated, low threshold Incomplete, weak, or fragmented Completely absent
- Grasp Reflex Exaggerated, tight Weak or sluggish Completely absent
Oculomotor & Pupils Dilated pupils (mydriasis), reactive Constricted pupils (miosis) , sluggish; disconjugate gaze Fixed, dilated, or nonreactive pupils ; absent corneal / doll's-eye reflex
Autonomic Function Sympathetic predominance: tachycardia, dry mucous membranes Parasympathetic predominance: bradycardia , copious oral secretions Both systems depressed: severe bradycardia, periodic breathing, apnea
Seizures None Common (>50%) : subtle, clonic, or tonic seizures Frequent / Status Epilepticus , refractory to medications
aEEG / EEG Background Normal continuous voltage or mildly discontinuous Discontinuous voltage, moderate abnormalities, focal/multifocal seizures Burst suppression , continuous low voltage, or isoelectric (flat)
Typical Duration <24 hours (resolves within 24–48h) 2 to 14 days Days to weeks (if survives)
Long-Term Prognosis >95% completely normal neurodevelopment 20% to 30% develop cerebral palsy, cognitive deficits, or epilepsy 50% to 75% mortality ; >80% of survivors have severe neurodisability
3. Therapeutic Hypothermia (Targeted Temperature Management)
Therapeutic hypothermia (TTM) is the single proven, evidence-based neuroprotective medical therapy for neonates with moderate to severe HIE. Large multicenter randomized controlled trials (including the NICHD, TOBY, and CoolCap trials) have demonstrated that lowering deep brain temperature by 3°C to 4°C significantly reduces mortality and severe neurodevelopmental disability at 18 to 24 months of age and improves long-term cognitive and motor outcomes into middle childhood.
Cellular Mechanisms of Neuroprotection
Suppression of Apoptosis: Inhibits mitochondrial cytochrome c release, suppresses caspase-3 activation, and downregulates pro-apoptotic proteins (Bax) while preserving anti-apoptotic factors (Bcl-2).
Metabolic Preservation: Reduces cerebral metabolic rate for glucose and oxygen by approximately 5% to 8% for every 1°C decrease in temperature , preserving vital cellular ATP stores.
Excitotoxicity Inhibition: Decreases extracellular glutamate accumulation and downregulates NMDA receptor activation.
Anti-Inflammatory & Antioxidant Actions: Inhibits microglial activation, reduces pro-inflammatory cytokine release (TNF-α, IL-1β), suppresses inducible nitric oxide synthase, and blunts free radical production and lipid peroxidation.
Clinical Eligibility & Inclusion Criteria
Therapeutic hypothermia must be initiated strictly within 6 hours of birth to capture the latent therapeutic window. Candidates must meet criteria across all three defined tiers:
Gestational Age & Timing:
Gestational age ≥ 35 to 36 weeks (safety and efficacy in preterm infants <35 weeks have not been established in standard clinical practice).
Postnatal age ≤ 6 hours of life .
Evidence of Acute Intrapartum Perinatal Asphyxia (At least ONE of the following):
Apgar score ≤ 5 at 10 minutes of life.
Continued need for positive pressure ventilation (PPV), endotracheal intubation, or CPAP at 10 minutes of life.
Severe metabolic or mixed acidemia: Cord blood gas or arterial/venous/capillary blood gas within 60 minutes of birth showing p H ≤ 7.00 pH \le 7.00 p H ≤ 7.00 OR Base Deficit (BD) ≥ 16 mmol/L \ge 16\text{ mmol/L} ≥ 16 mmol/L .
Acute perinatal event (placental abruption, uterine rupture, umbilical cord prolapse) with blood gas p H = 7.01 to 7.15 pH = 7.01\text{ to }7.15 p H = 7.01 to 7.15 OR Base Deficit = 10.0 to 15.9 mmol/L = 10.0\text{ to }15.9\text{ mmol/L} = 10.0 to 15.9 mmol/L .
Evidence of Moderate or Severe Neonatal Encephalopathy:
Documented moderate or severe encephalopathy on standardized neurological examination ( presence of signs in ≥ 3 of the 6 Sarnat categories : level of consciousness, spontaneous activity, posture, tone, primitive reflexes, or autonomic pupils/heart rate), OR
Clinical seizures, OR
Amplitude-integrated EEG (aEEG) demonstrating moderate or severe abnormal background activity (discontinuous low voltage, burst suppression, or status epilepticus).
Exclusion Criteria
Postnatal age > 6 hours (unless enrolled in specialized clinical trial protocols).
Severe lethal congenital anomalies or known lethal chromosomal aneuploidies (e.g., Trisomy 13 or 18).
Clinically significant, uncontrollable systemic coagulopathy with active, life-threatening hemorrhage (e.g., massive pulmonary hemorrhage or severe intracranial hemorrhage).
Severe congenital diaphragmatic hernia (CDH) or other major structural surgical anomalies requiring emergent operative repair.
Loading diagram... Therapeutic Hypothermia (TTM) Decision Pathway & Clinical Timeline
4. Therapeutic Hypothermia Protocol & Multisystem Physiological Management
Targeted temperature management is achieved using either whole-body cooling (water-circulating thermal blanket with servo-controlled feedback) or selective head cooling (cooling cap with mild systemic hypothermia). Contemporary neonatal units predominantly utilize whole-body cooling due to uniform core temperature control and ease of continuous aEEG and neurological assessment.
Cooling Protocol Specifications
Target Core Body Temperature: Maintain core body temperature at 33.5°C (acceptable range: 33.0°C to 34.0°C) .
Duration of Hypothermia: Exactly 72 hours of continuous active cooling.
Temperature Monitoring: Continuous core temperature monitoring using an indwelling esophageal temperature probe (placed in the lower third of the esophagus, approximately T8–T9, correlating with cardiac and deep brain temperature) or an indwelling rectal temperature probe inserted 2 to 3 cm past the anal sphincter and secured to the inner thigh. Axillary or skin temperatures are completely inadequate for servo-control.
Multisystem Physiological Changes & Nursing Interventions
Organ System Physiological Response to Hypothermia Critical Nursing Assessment & Clinical Management
Cardiovascular • Physiologic Sinus Bradycardia: Resting heart rate drops to 80–100 bpm (HR drops ~10 bpm per 1°C decrease in core temp).; • Mild systemic vasoconstriction and elevated systemic vascular resistance (SVR).; • Prolongation of PR, QRS, and QTc intervals. • Do NOT treat sinus bradycardia with atropine or pacing if mean arterial pressure (MAP) and capillary refill (<3s) remain adequate; bradycardia is an expected, protective physiological response.; • Maintain continuous arterial line or automated blood pressure monitoring.; • Treat true hypotension (MAP < gestational age) with isotonic crystalloids (10 mL/kg NS) and inotropes (dopamine, dobutamine, hydrocortisone).
Respiratory • Decreased metabolic rate, reduced O 2 O_2 O 2 consumption, and decreased C O 2 CO_2 C O 2 production.; • Increased blood gas solubility (uncorrected blood gas analyzed at 37°C will read higher P a O 2 PaO_2 P a O 2 and P a C O 2 PaCO_2 P a C O 2 ). • Maintain mechanical ventilation or CPAP as indicated.; • Avoid Hypocapnia ( P a C O 2 < 35 mmHg PaCO_2 < 35\text{ mmHg} P a C O 2 < 35 mmHg ): Hypocapnia causes severe cerebral vasoconstriction, decreasing cerebral blood flow and aggravating ischemic brain injury. Target P a C O 2 PaCO_2 P a C O 2 between 45 and 55 mmHg .; • Maintain normoxia ( P a O 2 PaO_2 P a O 2 60–80 mmHg, S p O 2 SpO_2 Sp O 2 92–96%); avoid severe hyperoxia.
Fluids & Renal • Risk of Syndrome of Inappropriate Antidiuretic Hormone (SIADH) and Acute Tubular Necrosis (ATN) from asphyxial renal injury.; • Decreased insensible water loss under cooling. • Restrict total fluid intake to 40–60 mL/kg/day for the first 24–48 hours to prevent cerebral edema and volume overload.; • Insert indwelling urinary catheter; maintain accurate urine output (target > 1.0 mL/kg/hour ).; • Monitor daily serum creatinine, BUN, and urine specific gravity.
Electrolytes & Metabolic • Hypokalemia: Intracellular shift of potassium ions during hypothermia.; • Hypocalcemia, hypomagnesemia, and hyperglycemia (decreased insulin release). • Monitor serum electrolytes every 6 to 12 hours.; • Correct hypocalcemia (maintain ionized calcium > 1.0 mmol/L) and hypomagnesemia to prevent lowering of seizure threshold.; • Supplement potassium with caution during cooling; remember that potassium will shift back out of cells during rewarming.
Hematology & Coagulation • Thrombocytopenia (platelet sequestration in spleen and liver).; • Coagulopathy: hypothermia slows hepatic clotting factor enzyme kinetics and impairs platelet aggregation. • Monitor platelet count, PT/INR, PTT, and fibrinogen.; • Transfuse platelets to maintain count > 50,000/μL (or > 100,000/μL if active bleeding or requiring invasive lines).; • Administer Fresh Frozen Plasma (FFP) or cryoprecipitate for clinical bleeding with prolonged clotting times.
Pharmacokinetics • Reduced hepatic cytochrome P450 metabolism and decreased renal clearance.; • Prolonged half-lives of opioids, sedatives, and anticonvulsants (phenobarbital). • Adjust dosing intervals and monitor serum medication levels (e.g., phenobarbital levels, gentamicin troughs).; • Monitor for drug toxicity and excessive sedation.
Neurological & Comfort • Shivering response increases metabolic rate, oxygen consumption, and stress.; • Clinical and subclinical electrographic seizures. • Administer continuous or intermittent low-dose IV opioids (morphine 10–20 mcg/kg/hr or fentanyl 0.5–1.0 mcg/kg/hr) for comfort and shivering suppression.; • Maintain continuous amplitude-integrated EEG ( aEEG ) throughout the 72 hours of cooling and 24 hours post-rewarming to detect subclinical electrographic seizures.
5. Rewarming Phase Nursing Protocols & Safety Vigilance
The rewarming phase begins promptly at the conclusion of the 72-hour cooling period . Rewarming is a high-risk transition period requiring intensive bedside nursing vigilance and strict adherence to slow, controlled thermal protocols.
Controlled Rewarming Protocol
Rate of Rewarming: Increase the core body temperature slowly and incrementally at a maximum rate of 0.5°C every 1 to 2 hours .
Rewarming Duration: The entire rewarming process must take 6 to 8 hours to reach a target normothermic core temperature of 36.5°C to 37.0°C .
Servo-Control Maintenance: Maintain continuous esophageal or rectal servo-control probe connection throughout the rewarming phase. Never use manual heating lamps, direct heating pads, or rapid radiant warmer adjustments.
Critical Rewarming Complications & Nursing Alerts +---------------------------------------------------------------------------------------------------+
- | REWARMING COMPLICATION CASCADE |
- | |
- | Rapid Temperature Rise --> Peripheral Vasodilation --> Acute Systemic Hypotension |
- | Cellular K+ Efflux --> Extracellular K+ Surge --> REBOUND HYPERKALEMIA & Arrhythmias |
- | Metabolic Surge --> Increased Cortical Demand --> SECONDARY SEIZURE EMERGENCE |
- | Fever Spike (>37.5°C) --> Neuroinflammation Surge --> WORSE NEURODEVELOPMENTAL OUTCOME |
- +---------------------------------------------------------------------------------------------------+
Rebound Systemic Hypotension:
As peripheral vascular beds warm, sudden cutaneous and splanchnic vasodilation occurs, expanding the intravascular space. This precipitous drop in systemic vascular resistance (SVR) can cause acute hypotension and decreased cerebral perfusion pressure.
Nursing Action: Monitor continuous arterial blood pressure; have isotonic crystalloid boluses (normal saline 10 mL/kg) and inotropes readily available at the bedside.
Rebound Hyperkalemia:
Potassium ions that shifted intracellularly during hypothermia rapidly exit cells and enter the intravascular compartment as core body temperature increases.
Nursing Action: Discontinue potassium-containing IV fluids prior to initiating rewarming. Check serum potassium every 2 to 4 hours during rewarming; treat severe hyperkalemia ( K + > 6.5 mEq/L K^+ > 6.5\text{ mEq/L} K + > 6.5 mEq/L with ECG changes) promptly with IV calcium gluconate, sodium bicarbonate, or insulin/glucose infusion.
Secondary Seizure Emergence:
Increasing cerebral temperature elevates cerebral metabolic demand and neuronal excitability. Electrographic seizures frequently emerge or worsen during rewarming.
Nursing Action: Maintain continuous video-EEG or aEEG throughout rewarming and for at least 24 hours post-rewarming . Have rescue anticonvulsants (phenobarbital, levetiracetam) immediately available.
Prevention of Post-Rewarming Hyperthermia / Pyrexia:
Post-ischemic fever ( > 37.5 ° C > 37.5°C > 37.5° C ) severely accelerates neuronal injury, negating the neuroprotective benefits of cooling.
Nursing Action: Strictly maintain normothermia (36.5°C–37.0°C); avoid overheating under radiant warmers or incubators.